{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.18","value":"4.6"},{"groupId":"OG001","spread":"27.52","value":"0.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"147"}],"units":"Participants"}],"title":"Loss of Appetite"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.24","value":"4.5"},{"groupId":"OG001","spread":"28.75","value":"1.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"148"}],"units":"Participants"}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.08","value":"-9.1"},{"groupId":"OG001","spread":"27.88","value":"-10.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"148"}],"units":"Participants"}],"title":"Cough"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.32","value":"-2.8"},{"groupId":"OG001","spread":"23.67","value":"-1.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"146"}],"units":"Participants"}],"title":"Dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.92","value":"-1.1"},{"groupId":"OG001","spread":"7.81","value":"-1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"147"}],"units":"Participants"}],"title":"Hemoptysis"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.22","value":"-4.2"},{"groupId":"OG001","spread":"26.64","value":"-7.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"147"}],"units":"Participants"}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.22","value":"-3.1"},{"groupId":"OG001","spread":"27.11","value":"-7.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"146"}],"units":"Participants"}],"title":"Overall Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.01","value":"2.5"},{"groupId":"OG001","spread":"24.91","value":"-3.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"146"}],"units":"Participants"}],"title":"Quality of Life"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.15","value":"3.2"},{"groupId":"OG001","spread":"31.39","value":"-4.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"title":"Interference"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.35","value":"-0.9"},{"groupId":"OG001","spread":"13.11","value":"-3.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"138"}],"units":"Participants"}],"title":"Average Symptom Burden Index (ASBI)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.59","value":"0.1"},{"groupId":"OG001","spread":"13.90","value":"-4.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"132"}],"units":"Participants"}],"title":"LCSS Total Score"}],"denoms":[{"counts":[{"groupId":"OG000","value":"315"},{"groupId":"OG001","value":"318"}],"units":"Participants"}],"description":"The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms \\[loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain\\] and 3 items were global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-mm lines. A higher score for any item represented a higher level of symptoms/problems. Scores for each of the reported categories ranged from 0 (for best outcome) to 100 (for worst outcome). The Average Symptom Burden Index (ASBI) was the mean of the 6 symptom items of the LCSS, and the Total LCSS was the mean of all 9 LCSS items. ASBI and Total LCSS were not computed for a participant if he/she had 1 or more missing values for the 6 and 9 items, respectively.","dispersionType":"Standard Deviation","groups":[{"description":"Necitumumab + Pemetrexed + Cisplatin\n\nNecitumumab: 800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V. infusion\n\nPemetrexed: 500 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles\n\nCisplatin: 75 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles","id":"OG000","title":"Necitumumab + Pemetrexed + Cisplatin"},{"description":"Pemetrexed + Cisplatin\n\nPemetrexed: 500 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles\n\nCisplatin: 75 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles","id":"OG001","title":"Pemetrexed + Cisplatin"}],"paramType":"MEAN","populationDescription":"All randomized participants who had evaluable baseline and postbaseline LCSS data.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 6 (Cycle =3 Weeks)","title":"Mean Change From Baseline in PRO as Measured Using the Lung Cancer Symptom Scale (LCSS)","type":"SECONDARY","unitOfMeasure":"millimeter (mm)"}